PeptoBismol® Use to Reduce Gastrointestinal Events in Healthy Volunteers Receiving DMF [Tecfidera®] Twice Daily

Inclusion Criteria:

- Must be in good health as determined by the Principal Investigator (PI) based on
medical history and Screening evaluations (clinical laboratory evaluations, 12-lead
electrocardiogram (ECG), and vital signs; see below for specific exclusion criteria).

- Must have a body mass index (BMI) of 18.0 to 34.0 kg/m2, inclusive.

- Subjects of reproductive potential (including males) must practice effective
contraception during the study and be willing and able to continue contraception for
90 days after their last dose of study drug.

- Male subjects must agree to not donate sperm for 90 days after their last dose of
study drug.

- Must be naïve to dimethyl fumarate (DMF) or fumaric acid esters.

Exclusion Criteria:

- History of or positive results at the Screening visit for HIV.

- History of or positive results at the Screening visit for hepatitis C virus antibody
or hepatitis B virus (defined as positive for hepatitis B surface antigen [HBsAg] or
hepatitis B core antibody [HBcAb]).

- History of clinically significant gastrointestinal (GI) disease as determined by the
PI (including Crohn's disease, peptic ulcer disease, ulcerative colitis, or confirmed
diagnosis of irritable bowel syndrome) or active GI disease with ongoing symptoms.

- History of severe allergic or anaphylactic reactions, considered clinically relevant
by the PI.

- Known allergy to Pepto-Bismol®, salicylates, or non-steroidal anti-inflammatory
drugs, considered clinically relevant by the PI.

- Female subjects who are pregnant based on results of the serum pregnancy test at
Screening or currently breastfeeding.

- Current enrollment in any other study treatment or disease study.

- Receipt of any investigational drug within 5 half-lives or 30 days, whichever is
longer, prior to study entry.

- History of alcohol abuse or substance abuse (as determined by the PI) within the
previous 5 years, a positive urine drug/alcohol test at Screening, or alcohol use
prior to the screening visit.

- Regular use of any tobacco product, defined as smoke or smokeless product use
equivalent to >5 cigarettes/day for any consecutive week, within 3 months prior to
Day 1.

Other unspecified reasons that, in the opinion of the PI or Biogen Idec, make the subject
unsuitable for enrollment.